| Assay ID | Title | Year | Journal | Article |
|---|
| AID319458 | Effect on TNF expression in mouse aP2-/- macrophage cells relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319416 | Effect on triglyceride level in 5-week old apoE-/- C57BL/6J mouse fed on western diet and 15 mg/kg/day, po drug simultaneously in 5-11 week early intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319442 | Effect on hormone-sensitive lipase in mouse aP2-/- macrophage cells at 25 uM after 24 hrs | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID601695 | Displacement of fluorescent 1-anilinonapthalene 8-sulfonic acid from human h-FABP by fluorescence spectrophotometry | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
| New aromatic substituted pyrazoles as selective inhibitors of human adipocyte fatty acid-binding protein. |
| AID1312067 | Direct binding to His6-tagged FABP4 (unknown origin) expressed in Escherichia coli BL21(DE3) cells by isothermal titration calorimetry | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
| The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation. |
| AID733213 | Inhibition of human FABP4 by 8-anilino-1-naphthalenesulfonic acid based fluorescence displacement assay | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Structure-guided design, synthesis and in vitro evaluation of a series of pyrazole-based fatty acid binding protein (FABP) 3 ligands. |
| AID1648441 | Antiinflammatory activity in C57BL/6J mouse assessed as reduction in LPS-induced IL6 secretion at 50 mg/kg, ig administered 1 hr before LPS stimulation and measured after 5 hrs by ELISA | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319419 | Effect on adiponectin level in 5-week old apoE-/- C57BL/6J mouse fed on western diet and 15 mg/kg/day, po drug simultaneously in 5-11 week early intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648452 | Reduction in LPS-induced spleen damage in C57BL/6J mouse at 25 mg/kg, ig administered for 4 days and measured by H and E staining-based microscopy analysis | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319461 | Decrease in fatty acid uptake in FABP-deficient mouse adipocytes reconstituted with exogenous aP2 after 24 hrs | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID660105 | Inhibition of LPS-stimulated TNFalpha production in mouse RAW264.7 cells at 10 umol/ml dosed simultaneously with LPS measured 24 hrs post dose by ELISA | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | Design, synthesis and biological evaluation of thiazole- and indole-based derivatives for the treatment of type II diabetes. |
| AID319425 | Effect on free fatty acid level in 5-week old apoE-/- C57BL/6J mouse fed on western diet and administered with 15 mg/kg/day, po drug at 12 week in 12-18 week late intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319449 | Reduction of IL1-beta expressed in mouse aP2-/-R macrophage cells (re-expression of aP2) relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID601696 | Antiinflammatory activity in rat RAW264.7 cells assessed as inhibition of lipopolysaccharide induced TNF-alpha mRNA expression by PCR | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
| New aromatic substituted pyrazoles as selective inhibitors of human adipocyte fatty acid-binding protein. |
| AID319447 | Reduction of IL1-beta expression in human THP1 cells expressing aP2 relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319451 | Reduction of IL6 expression in human THP1 cells expressing aP2 relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319445 | Reduction of Mcp1 expression mouse aP2-/-R macrophage cells (re-expression of aP2) relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319407 | Decrease in MCP1 production in mouse aP2+/+ macrophage cells after 24 hrs | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648415 | Cytotoxicity against mouse 3T3L1 cells assessed as reduction in cell viability at 20 and 50 uM incubated for 24 hrs by CCK8 assay | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319473 | Suppression of clamp hepatic glucose production in ob/ob mouse at 40 mg/kg/day, po after 4 weeks by hyperinsulinemic-euglycaemic clamp studies | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319427 | Effect on adiponectin level in 5-week old apoE-/- C57BL/6J mouse fed on western diet and administered with 15 mg/kg/day, po drug at 12 week in 12-18 week late intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319444 | Reduction of Mcp1 expression mouse aP2+/+ macrophage cells relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1312066 | Binding affinity to His6-tagged FABP4 (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as change in melting temperature at 50 uM after 30 mins by SYPRO orange dye based thermal stability shift assay | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
| The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation. |
| AID1648408 | Displacement of 1,8-ANS from recombinant human 6His-tagged FABP3 expressed in Escherichia coli BL21 DE3 incubated for 15 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based assay | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID1648413 | Antiinflammatory activity in human THP1 cells assessed as reduction in LPS-induced IL6 secretion at 20 uM incubated for 18 hrs followed by LPS stimulation and measured after 6 hrs by ELISA | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319429 | Reduction of cholesterol ester accumulation in human THP1 cells at 25 uM after 4 days relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648450 | Reduction in LPS-induced liver damage in C57BL/6J mouse at 25 mg/kg, ig administered for 4 days and measured by H and E staining-based microscopy analysis | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319485 | Attenuation of JNK1 activity in ob/ob mouse adipose tissue at 40 mg/kg/day, po | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319459 | Decrease in fatty acid uptake in wild type mouse aP2+/+ mal1+/+ preadipocytes after 24 hrs | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID733214 | Inhibition of human FABP3 by 8-anilino-1-naphthalenesulfonic acid based fluorescence displacement assay | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Structure-guided design, synthesis and in vitro evaluation of a series of pyrazole-based fatty acid binding protein (FABP) 3 ligands. |
| AID319488 | Effect on aP2 level in ob/ob mouse adipose tissue at 40 mg/kg/day, po after 6 weeks | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319493 | Decrease in Fasn expression in liver of ob/ob mouse at 40 mg/kg/day, po | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319440 | Effect on hormone-sensitive lipase in mouse aP2+/+ macrophage cells at 25 uM after 24 hrs | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319472 | Effect on glycerol level in ob/ob mouse at 40 mg/kg/day, po after 6 weeks relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319415 | Effect on cholesterol level in 5-week old apoE -/- C57BL/6J mouse fed on western diet and 15 mg/kg/day, po drug simultaneously in 5-11 week early intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319448 | Reduction of IL1-beta expressed in mouse aP2+/+ macrophage cells relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319433 | Increase in APOA1-mediated cholesterol in human THP1 cells at 25 uM relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319454 | Effect on IL6 expression mouse aP2-/- macrophage cells relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319496 | Increase in insulin-stimulated IRbeta tyrosine 1162/1163 phosphorylation in ob/ob mouse liver at 40 mg/kg/day, po relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319420 | Effect on body weight in 5-week old apoE-/- C57BL/6J mouse fed on western diet and administered with 15 mg/kg/day, po drug at 12 week in 12-18 week late intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319428 | Reduction of transformation of human THP1 cells to foam cells at 25 uM after 3 days relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648407 | Binding affinity at recombinant human 6His-tagged FABP4 expressed in Escherichia coli BL21 DE3 by isothermal titration calorimetry | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319476 | Increase in glucose uptake in epididymal fat in ob/ob mouse at 40 mg/kg/day, po after 4 weeks by hyperinsulinemic-euglycaemic clamp studies relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319483 | Decrease in IL6 expression in ob/ob mouse adipose tissue at 40 mg/kg/day, po | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID733212 | Selectivity ratio of IC50 for human FABP4 over IC50 for human FABP3 | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
| Structure-guided design, synthesis and in vitro evaluation of a series of pyrazole-based fatty acid binding protein (FABP) 3 ligands. |
| AID319455 | Reduction of TNF expression in human THP1 cells expressing aP2 relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319412 | Effect on body weight in 5-week old apoE-/- C57BL/6J mouse fed on western diet and 15 mg/kg/day, po drug simultaneously in 5-11 week early intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319437 | Increase in cholesterol efflux in mouse aP2-/-R macrophage cells (re-expression of aP2) at 25 uM relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319446 | Effect on Mcp1 expression mouse aP2-/- macrophage cells relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319434 | Increase in ABCA1 mRNA level in human THP1 cells at 25 uM relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648453 | Hepatoprotective activity in C57BL/6J mouse assessed as reduction in LPS-induced AST level at 25 mg/kg, ig administered before LPS stimulation for 4 days and measured on day 5 | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319406 | Decrease in MCP1 production in human THP1 cells expressing aP2 after 24 hrs | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648449 | Reduction in LPS-induced lung damage in C57BL/6J mouse at 25 mg/kg, ig administered for 4 days and measured by H and E staining-based microscopy analysis | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID601694 | Displacement of fluorescent 1-anilinonapthalene 8-sulfonic acid from human a-FABP by fluorescence spectrophotometry | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
| New aromatic substituted pyrazoles as selective inhibitors of human adipocyte fatty acid-binding protein. |
| AID319443 | Reduction of Mcp1 expression in human THP1 cells expressing aP2 relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319471 | Increase in free fatty acid level in ob/ob mouse at 40 mg/kg/day, po after 6 weeks relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319414 | Effect on insulin level in 5-week old apoE-/- C57BL/6J mouse fed on western diet and 15 mg/kg/day, po drug simultaneously in 5-11 week early intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648406 | Displacement of 1,8-ANS from recombinant human 6His-tagged FABP4 expressed in Escherichia coli BL21 DE3 incubated for 15 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based assay | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319430 | Reduction in total cholesterol ester content in mouse aP2+/+ macrophage cells at 25 uM relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319478 | Decrease in glucose level in FABP-deficient mouse fed on high fat diet after 4 weeks by glucose tolerance test relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319481 | Decrease in Mcp1 expression in ob/ob mouse adipose tissue at 40 mg/kg/day, po | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319463 | Decrease in blood glucose level in fasted ob/ob mouse at 40 mg/kg/day, po after 6 weeks | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID307909 | Displacement of 1,8-ANS from eFABP by fluorescence based-assay | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
| Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). |
| AID319453 | Reduction of IL6 expression mouse aP2-/-R macrophage cells (re-expression of aP2) relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1312068 | Inhibition of FABP4 in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
| The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation. |
| AID307910 | Displacement of [3H]2,3-bis[(2,4-dichlorobenzyl)oxy]benzoic acid from aFABP | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
| Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). |
| AID319474 | Increase in whole body glucose disposal and glucose infusion rate in ob/ob mouse at 40 mg/kg/day, po after 4 weeks by hyperinsulinemic-euglycaemic clamp studies | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319487 | Increase in insulin-stimulated AKT serine 473 phosphorylation in ob/ob mouse adipose tissue at 40 mg/kg/day, po relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648440 | Antiinflammatory activity in C57BL/6J mouse assessed as reduction in LPS-induced MCP1 secretion at 50 mg/kg, ig administered 1 hr before LPS stimulation and measured after 5 hrs by ELISA | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319479 | Decrease in F4/80 (Emr1) expression in ob/ob mouse adipose tissue at 40 mg/kg/day, po | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319422 | Effect on insulin level in 5-week old apoE-/- C57BL/6J mouse fed on western diet and administered with 15 mg/kg/day, po drug at 12 week in 12-18 week late intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID660106 | Inhibition of rat ap2 by fluorescent 1,8-anilino-8-naphthalene sulfonate assay | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | Design, synthesis and biological evaluation of thiazole- and indole-based derivatives for the treatment of type II diabetes. |
| AID319468 | Decrease in insulin level in ob/ob mouse plasma at 40 mg/kg/day, po after 6 weeks relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319408 | Effect on MCP1 production in mouse aP2-/- macrophage cells after 24 hrs | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319432 | Effect on cholesterol ester content in mouse aP2-/- macrophages at 25 uM relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319435 | Increase in ABCA1 protein level in human THP1 cells at 25 uM relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319494 | Decrease in Acaca expression in liver of ob/ob mouse at 40 mg/kg/day, po | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319492 | Decrease in Scd1 expression in liver of ob/ob mouse at 40 mg/kg/day, po | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319423 | Effect on cholesterol level in 5-week old apoE-/- C57BL/6J mouse fed on western diet and administered with 15 mg/kg/day, po drug at 12 week in 12-18 week late intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319462 | Decrease in blood glucose level in fed ob/ob mouse at 40 mg/kg/day, po after 2 weeks | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319470 | Increase in adiponectin level in ob/ob mouse plasma at 40 mg/kg/day, po after 6 weeks relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1305257 | Binding affinity to His-tagged human recombinant FABP4 expressed in Escherichia coli BL21 (DE3) by fluorescence assay | 2016 | ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
| Interaction Analysis of FABP4 Inhibitors by X-ray Crystallography and Fragment Molecular Orbital Analysis. |
| AID319477 | Decrease in glucose level in wild type mouse fed on high fat diet after 4 weeks by glucose tolerance test relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319417 | Effect on free fatty acid level in 5-week old apoE-/- C57BL/6J mouse fed on western diet and 15 mg/kg/day, po drug simultaneously in 5-11 week early intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319467 | Effect on cholesterol level in ob/ob mouse at 40 mg/kg/day, po after 6 weeks relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1312065 | Displacement of 1,8-ANS from His6-tagged FABP4 (unknown origin) expressed in Escherichia coli BL21(DE3) cells by fluorescence assay | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
| The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation. |
| AID601697 | Antiinflammatory activity in rat RAW264.7 cells assessed as inhibition of lipopolysaccharide induced MCP-1/CCL2 mRNA expression by PCR | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
| New aromatic substituted pyrazoles as selective inhibitors of human adipocyte fatty acid-binding protein. |
| AID319450 | Effect on IL1-beta expressed in mouse aP2-/- macrophage cells relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648412 | Antiinflammatory activity in human THP1 cells assessed as reduction in LPS-induced MCP1 secretion at 20 uM incubated for 18 hrs followed by LPS stimulation and measured after 6 hrs by ELISA | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319497 | Increase in insulin-stimulated AKT serine 473 phosphorylation in ob/ob mouse liver at 40 mg/kg/day, po relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648455 | Nephroprotective activity in C57BL/6J mouse assessed as reduction in LPS-induced BUN level at 25 mg/kg, ig administered before LPS stimulation for 4 days and measured on day 5 | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319436 | Increase in cholesterol efflux in mouse aP2+/+ macrophage cells at 25 uM relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319457 | Reduction of TNF expression mouse aP2-/-R macrophage cells (re-expression of aP2) relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319413 | Effect on glucose level in 5-week old apoE -/- C57BL/6J mouse fed on western diet and 15 mg/kg/day, po drug simultaneously in 5-11 week early intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648454 | Hepatoprotective activity in C57BL/6J mouse assessed as reduction in LPS-induced ALT level at 25 mg/kg, ig administered before LPS stimulation for 4 days and measured on day 5 | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319421 | Effect on glucose level in 5-week old apoE-/- C57BL/6J mouse fed on western diet and administered with 15 mg/kg/day, po drug at 12 week in 12-18 week late intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319480 | Decrease in Cd68 expression in ob/ob mouse adipose tissue at 40 mg/kg/day, po | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319456 | Reduction of TNF expression in mouse aP2+/+ macrophage cells relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319486 | Increase in insulin-stimulated IRbeta tyrosine 1162/1163 phosphorylation in ob/ob mouse adipose tissue at 40 mg/kg/day, po relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1312070 | Inhibition of FABP4 in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 expression after 24 hrs by qPCR method | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
| The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation. |
| AID319460 | Effect on fatty acid uptake in FABP-deficient mouse aP2-/- mal1-/- preadipocytes after 24 hrs | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319464 | Increase in glucose metabolism in ob/ob mouse at 40 mg/kg/day, po after 4 weeks by glucose tolerance test | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319439 | Effect on hormone-sensitive lipase in human THP1 cells expressing aP2 at 25 uM after 24 hrs | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID307907 | Displacement of 1,8-ANS from aFABP by fluorescence based-assay | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
| Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). |
| AID1312069 | Inhibition of FABP4 in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha expression after 24 hrs by qPCR method | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
| The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation. |
| AID1648409 | Displacement of 1,8-ANS from recombinant human 6His-tagged FABP5 expressed in Escherichia coli BL21 DE3 incubated for 15 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based assay | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319431 | Reduction in total cholesterol ester content in mouse aP2-/-R macrophage cells (re-expression of aP2) at 25 uM relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319484 | Decrease in TNF expression in ob/ob mouse adipose tissue at 40 mg/kg/day, po | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319438 | Increase in cholesterol efflux in mouse aP2-/- macrophage cells at 25 uM relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648410 | Selectivity index, ratio of Ki for recombinant human 6His-tagged FABP3 expressed in Escherichia coli BL21 DE3 to Ki for recombinant human 6His-tagged FABP4 expressed in Escherichia coli BL21 DE3 | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319475 | Increase in glucose uptake in gastrocnemius muscle in ob/ob mouse at 40 mg/kg/day, po after 4 weeks by hyperinsulinemic-euglycaemic clamp studies relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319418 | Effect on glycerol level in 5-week old apoE-/- C57BL/6J mouse fed on western diet and 15 mg/kg/day, po drug simultaneously in 5-11 week early intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648451 | Reduction in LPS-induced kidney damage in C57BL/6J mouse at 25 mg/kg, ig administered for 4 days and measured by H and E staining-based microscopy analysis | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319482 | Decrease in IL1-beta expression in ob/ob mouse adipose tissue at 40 mg/kg/day, po | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319466 | Effect on pancreatic morphology in ob/ob mouse at 40 mg/kg/day, po | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319452 | Reduction of IL6 expression mouse aP2+/+ macrophage cells relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319490 | Attenuation of fatty infiltration of liver in ob/ob mouse at 40 mg/kg/day, po | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319411 | Inhibition of aP2 in 5-week old apoE-/- C57BL/6J mouse fed on western diet and administered with 15 mg/kg/day, po drug at 12 week in late intervention study assessed as reduction of atherosclerotic lesion in en face aorta relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319426 | Effect on glycerol level in 5-week old apoE-/- C57BL/6J mouse fed on western diet and administered with 15 mg/kg/day, po drug at 12 week in 12-18 week late intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319409 | Decrease in MCP1 production in mouse aP2-/-R macrophage cells (re-expression of aP2) after 24 hrs | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319489 | Effect on mal1 protein level in ob/ob mouse adipose tissue at 40 mg/kg/day, po after 6 weeks | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319441 | Effect on hormone-sensitive lipase in mouse aP2-/-R macrophage cells (re-expression of aP2) at 25 uM after 24 hrs | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319495 | Inhibition of JNK1 activity in ob/ob mouse liver at 40 mg/kg/day, po relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319469 | Decrease in triglyceride level in ob/ob mouse at 40 mg/kg/day, po after 6 weeks relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1648416 | Inhibition of FABP4 in mouse 3T3L1 cells assessed as inhibition of forskolin-stimulated lipolysis by measuring free glycerol at 1 to 25 uM incubated for 24 hrs followed by forskolin stimulation and measured after 2 hrs | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation. |
| AID319491 | Reduction of total liver triglyceride level in ob/ob mouse at 40 mg/kg/day, po | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319410 | Inhibition of aP2 in 5-week old apoE -/- C57BL/6J mouse fed on western diet and 15 mg/kg/day, po drug simultaneously in early intervention study assessed as reduction of atherosclerotic lesion in en face aorta relative to control | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID319465 | Increase in insulin sensitivity in ob/ob mouse at 40 mg/kg/day, po after 5 weeks by insulin tolerance test | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID307908 | Displacement of 1,8-ANS from mFABP by fluorescence based-assay | 2007 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
| Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). |
| AID319424 | Effect on triglyceride level in 5-week old apoE-/- C57BL/6J mouse fed on western diet and administered with 15 mg/kg/day, po drug at 12 week in 12-18 week late intervention study | 2007 | Nature, Jun-21, Volume: 447, Issue:7147
| Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. |
| AID1347161 | Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347164 | 384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347149 | Furin counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347168 | HepG2 cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347163 | 384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347167 | Vero cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347152 | Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347157 | Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347169 | Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347153 | Confirmatory screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1802031 | FABP1 Fluorescent Ligand Displacement Assay from Article 10.1021/acs.biochem.6b00446: \\FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.\\ | 2016 | Biochemistry, 09-20, Volume: 55, Issue:37
| FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein. |
| AID1347158 | ZIKV-mCherry secondary qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347156 | DAPI mCherry counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |